Editorial Comment to Local dose (biological effective dose <180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low‐dose‐rate brachytherapy

This publication has 5 references indexed in Scilit:

• Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low‐dose‐rate brachytherapy
  International Journal of Urology, 2022
• I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes
  Brachytherapy, 2020
• ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
• Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
• Multicenter Analysis of Effect of High Biologic Effective Dose on Biochemical Failure and Survival Outcomes in Patients With Gleason Score 7–10 Prostate Cancer Treated With Permanent Prostate Brachytherapy
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009